Home / Generic availability / Tirzepatide
When will generic Tirzepatide be available?
Based on the patents and exclusivity the FDA lists today, generic tirzepatide cannot be marketed in the United States before 2041-12-30, when the last listed protection expires.
Patents listed with the FDA
40 unexpired or current listing(s).
| Patent | Expires | Covers | Product |
|---|---|---|---|
| 9474780 | 2036-05-13 | drug substance, drug product | MOUNJARO (AUTOINJECTOR) |
| 9474780 | 2036-05-13 | drug substance, drug product | MOUNJARO |
| 9474780 | 2036-05-13 | drug substance, drug product | MOUNJARO KWIKPEN |
| 9474780 | 2036-05-13 | drug substance, drug product | ZEPBOUND (AUTOINJECTOR) |
| 9474780 | 2036-05-13 | drug substance, drug product | ZEPBOUND |
| 9474780 | 2036-05-13 | drug substance, drug product | ZEPBOUND KWIKPEN |
| 11357820 | 2039-06-14 | drug product | MOUNJARO (AUTOINJECTOR) |
| 12453755 | 2039-06-14 | method of use | MOUNJARO (AUTOINJECTOR) |
| 12453756 | 2039-06-14 | drug product | MOUNJARO (AUTOINJECTOR) |
| 12629404 | 2039-06-14 | drug product | MOUNJARO (AUTOINJECTOR) |
| 11357820 | 2039-06-14 | drug substance, drug product | MOUNJARO |
| 12453755 | 2039-06-14 | method of use | MOUNJARO |
| 12453756 | 2039-06-14 | drug product | MOUNJARO |
| 12629404 | 2039-06-14 | drug product | MOUNJARO |
| 11357820 | 2039-06-14 | drug product | ZEPBOUND (AUTOINJECTOR) |
| 11918623 | 2039-06-14 | method of use | ZEPBOUND (AUTOINJECTOR) |
| 12453756 | 2039-06-14 | drug product | ZEPBOUND (AUTOINJECTOR) |
| 12629404 | 2039-06-14 | drug product | ZEPBOUND (AUTOINJECTOR) |
| 11357820 | 2039-06-14 | drug product | ZEPBOUND |
| 11918623 | 2039-06-14 | method of use | ZEPBOUND |
| 12453756 | 2039-06-14 | drug product | ZEPBOUND |
| 12629404 | 2039-06-14 | drug product | ZEPBOUND |
| 12343382 | 2039-07-22 | method of use | MOUNJARO (AUTOINJECTOR) |
| 12616740 | 2039-07-22 | method of use | MOUNJARO (AUTOINJECTOR) |
| 12343382 | 2039-07-22 | method of use | MOUNJARO |
| 12616740 | 2039-07-22 | method of use | MOUNJARO |
| 12343382 | 2039-07-22 | method of use | MOUNJARO KWIKPEN |
| 12616740 | 2039-07-22 | method of use | MOUNJARO KWIKPEN |
| 12343382 | 2039-07-22 | method of use | ZEPBOUND (AUTOINJECTOR) |
| 12453758 | 2039-07-22 | method of use | ZEPBOUND (AUTOINJECTOR) |
| 12616740 | 2039-07-22 | method of use | ZEPBOUND (AUTOINJECTOR) |
| 12343382 | 2039-07-22 | method of use | ZEPBOUND |
| 12453758 | 2039-07-22 | method of use | ZEPBOUND |
| 12616740 | 2039-07-22 | method of use | ZEPBOUND |
| 12343382 | 2039-07-22 | method of use | ZEPBOUND KWIKPEN |
| 12453758 | 2039-07-22 | method of use | ZEPBOUND KWIKPEN |
| 12616740 | 2039-07-22 | method of use | ZEPBOUND KWIKPEN |
| 12295987 | 2041-12-30 | method of use | MOUNJARO (AUTOINJECTOR) |
| 12295987 | 2041-12-30 | method of use | MOUNJARO |
| 12295987 | 2041-12-30 | method of use | MOUNJARO KWIKPEN |
FDA exclusivity
Exclusivity is granted by the FDA and runs separately from patents. It can block a generic even after a patent expires.
| Code | Expires | What it is | Product |
|---|---|---|---|
| NP | 2026-11-08 | New product | ZEPBOUND (AUTOINJECTOR) |
| NCE | 2027-05-13 | New chemical entity (5 years) | MOUNJARO (AUTOINJECTOR) |
| NCE | 2027-05-13 | New chemical entity (5 years) | MOUNJARO |
| NCE | 2027-05-13 | New chemical entity (5 years) | MOUNJARO KWIKPEN |
| NCE | 2027-05-13 | New chemical entity (5 years) | ZEPBOUND (AUTOINJECTOR) |
| NCE | 2027-05-13 | New chemical entity (5 years) | ZEPBOUND |
| NCE | 2027-05-13 | New chemical entity (5 years) | ZEPBOUND KWIKPEN |
| M-82 | 2027-10-18 | Exclusivity tied to a specific labelling or study change | ZEPBOUND (AUTOINJECTOR) |
| M-82 | 2027-10-18 | Exclusivity tied to a specific labelling or study change | ZEPBOUND |
| M-82 | 2027-10-18 | Exclusivity tied to a specific labelling or study change | ZEPBOUND KWIKPEN |
| I-958 | 2027-12-20 | New indication (3 years) | ZEPBOUND (AUTOINJECTOR) |
| I-958 | 2027-12-20 | New indication (3 years) | ZEPBOUND |
| I-958 | 2027-12-20 | New indication (3 years) | ZEPBOUND KWIKPEN |
| NPP | 2028-12-19 | New patient population | MOUNJARO (AUTOINJECTOR) |
| NPP | 2028-12-19 | New patient population | MOUNJARO |
| NPP | 2028-12-19 | New patient population | MOUNJARO KWIKPEN |
Approved products
| Product | Type | Applicant | Approved | |
|---|---|---|---|---|
| MOUNJARO, MOUNJARO (AUTOINJECTOR), MOUNJARO KWIKPEN | Brand (NDA) | ELI LILLY AND CO | 2022-05-13 | reference listed drug, reference standard |
| ZEPBOUND, ZEPBOUND (AUTOINJECTOR), ZEPBOUND KWIKPEN | Brand (NDA) | ELI LILLY AND CO | 2023-11-08 | reference listed drug, reference standard |
What a generic Tirzepatide would have to match
Forms and strengths
Injection: Clear, colorless to slightly yellow solution in pre-filled single-dose pens, single-dose vials, multi-dose vials, or single-patient-use KwikPens, each available in the following strengths. The multi-dose vials and single-patient-use KwikPen each contain 4 doses: Single-dose Pen or Vial 2.5 mg/0.5 mL 5 mg/0.5 mL 7.5 mg/0.5 mL 10 mg/0.5 mL 12.5 mg/0.5 mL 15 mg/0.5 mL Multi-dose Vial (4 doses per vial) Dose per Injection Total Strength per Total Volume Strength per mL 2.5 mg/0.6 mL 10 mg/2.4 mL 4.17 mg/mL 5 mg/0.6 mL 20 mg/2.4 mL 8.33 mg/mL 7.5 mg/0.6 mL 30 mg/2.4 mL 12.5 mg/mL 10 mg/0.6 mL 40 mg/2.4 mL 16.7 mg/mL 12.5 mg/0.6 mL 50 mg/2.4 mL 20.8 mg/mL 15 mg/0.6 mL 60 mg/2.4 mL 25 mg/mL Single-Patient-Use KwikPen (4 doses per KwikPen) Dose per Injection Total Strength per Total Volume Strength per mL 2.5 mg 10 mg/2.4 mL 4.17 mg/mL 5 mg 20 mg/2.4 mL 8.33 mg/mL 7.5 mg 30 mg/2.4 mL...
How it is supplied
16.1 How Supplied ZEPBOUND (tirzepatide) is a clear, colorless to slightly yellow solution available in cartons containing 4 pre-filled single-dose pens, 1 single-dose vial, 4 single-dose vials, 1 multi-dose vial, or 1 single-patient-use KwikPen as follows: Single-Dose Vial and Prefilled Pen Strength 4 pack Single-dose Pen NDC 1 pack Single-dose Vial NDC 4 pack Single-dose Vial NDC 2.5 mg/0.5 mL 0002-2506-80 0002-0152-01 0002-0152-04 5 mg/0.5 mL 0002-2495-80 0002-0243-01 0002-0243-04 7.5 mg/0.5 mL 0002-2484-80 0002-1214-01 0002-1214-04 10 mg/0.5 mL 0002-2471-80 0002-1340-01 0002-1340-04 12.5 mg/0.5 mL 0002-2460-80 0002-1423-01 0002-1423-04 15 mg/0.5 mL 0002-2457-80 0002-2002-01 0002-2002-04...
Storage
Do not freeze ZEPBOUND. Do not use ZEPBOUND if frozen. Protect ZEPBOUND from heat and light. Store ZEPBOUND in the original carton to protect from light. ZEPBOUND Single-dose Pen and Single-dose Vial Store ZEPBOUND single-dose pen and single-dose vial in a refrigerator at 2°C to 8°C (36°F to 46°F). If needed, each single-dose pen or single-dose vial can be stored unrefrigerated at temperatures not to exceed 30°C (86°F) for up to a total of 21 days. Discard single-dose pen and single-dose vial...
A generic has to match the reference product on active ingredient, strength, dosage form and route. These are the forms the FDA label currently lists. Source: FDA Structured Product Labeling, label effective 2026-08-28.
Recalls involving Tirzepatide
| Firm | State | Class | Initiated | Reason given |
|---|---|---|---|---|
| Houston Rx LLC | TX | Class II | 2026-09-25 | Lack of assurance of sterility. |
| Apothecary Pharma LLC | NC | Class II | 2026-09-24 | Lack of Assurance of Sterility |
| Carolina Infusion, LLC | SC | Class II | 2026-09-10 | Lack of Assurance of Sterility: Related to formulation using bacterios |
Supply history matters to availability: a recalled batch is a batch that did not reach patients. Most records here are compounded preparations rather than the approved product. Source: openFDA drug enforcement reports, checked 2026-11-09.
Other drugs and when their protection ends
Ordered by the date the last listed patent or exclusivity expires.
- Octreotideprotection runs to June 2027
- Terlipressinprotection runs to September 2027
- Abaloparatideprotection runs to October 2027
- Macimorelinprotection runs to October 2027
- Setmelanotideprotection runs to October 2027
Frequently asked questions
When will generic Tirzepatide be available?
Based on the patents and exclusivity the FDA lists today, generic tirzepatide cannot be marketed in the United States before 2041-12-30, when the last listed protection expires.
Does this date guarantee a generic launches then?
No. It is the date the last protection the FDA currently lists expires. Patents can be challenged, licensed, or designed around, which can bring a generic earlier, and new patents can be listed later. Treat it as the outer limit of the brand's protection, not a launch forecast.
What is the difference between a patent and exclusivity?
A patent is granted by the patent office and listed with the FDA by the brand. Exclusivity is granted by the FDA itself on approval. They run independently, and exclusivity can keep a generic off the market even after a patent has expired.
What is a tentative approval?
It means the FDA has reviewed a generic application and judged it acceptable, but cannot allow it to be marketed yet because patents or exclusivity are still running. It is the clearest signal that a generic is ready to launch once the dates clear.
Source: FDA Orange Book via openFDA, with tentative-approval data from Drugs@FDA. Last updated 2026-11-01. Do not rely on this page to make decisions regarding medical care; always speak to your health provider about the risks and benefits of FDA-regulated products.
Related data
- Tirzepatide clinical trials →Registered studies, phases and status
- Which peptides are FDA-approved →Approval status for every peptide, from Drugs@FDA
- FDA drug shortage tracker →Which peptide drugs are in shortage now, with the FDA-stated cause
- When peptide drugs go generic →Patent and exclusivity expiry dates from the FDA Orange Book
More from Peptides.io
- GLP-1 Treatment Gap Index →Our analysis of where Medicaid access to GLP-1s falls shortest, by state
- Original research from Peptides.io →Data reports we produce ourselves
